The Global Antibiotic Research and Development Partnership (GARDP) said yesterday that an international clinical trial ...
India has enrolled its first newborn in the global NeoSep1 trial at JIPMER, Puducherry. The study will test antibiotic ...
Neonatal sepsis is a leading cause of infant morbidity and mortality in low- and middle-income countries (LMICs), yet despite ...
A major multi-country study has found that WHO-recommended first-line antibiotics for neonatal sepsis are likely to be effective in only one-quarter of infections in low- and middle-income countries ...
Sepsis leads to life-threatening organ failure due to dysregulated host responses to infection and presents uniquely across age groups. Neonatal sepsis, affecting infants in their first 28 days, ...
LISBON, Portugal — A shift toward broader-spectrum antibiotics and increasing antibiotic resistance has led to high levels of mortality and neurodevelopmental impacts in surviving babies, according to ...